Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic Annual Analyst Meeting In Brief

This article was originally published in The Gray Sheet

Executive Summary

"Paranoid" but not "paralyzed": The recent spate of Guidant recalls is not causing a "material dampening effect on the marketplace," Cardiac Rhythm Management President Steve Mahle said Oct. 11 at the firm's annual analyst meeting in Minneapolis, though he admitted that "anytime your business becomes a front page article repeatedly in the newspapers is usually not good." Mahle, who stressed Medtronic's work with AdvaMed to help determine when firms should notify patients and physicians of potential problems with their medical devices, said that the "biggest issue we have to deal with...is putting things into perspective." He added: "Survivors have to be paranoid. We're sufficiently paranoid, but we're not paranoid where we're paralyzed in terms of doing what's right for the business"...

You may also be interested in...



Chilly Japanese Medical Device Climate Draws Fire From Hill, Industry

Japan's regulatory and reimbursement systems came under fire this week from lawmakers on Capitol Hill and attendees of AdvaMed's international conference in Arlington, Va

Medtronic’s Restore, W.L. Gore’s Tag Receive New Tech Add-On Payment

Medtronic's argument that the Restore rechargeable implantable neurostimulator represents a substantial clinical improvement over existing devices convinced CMS to award the device new technology add-on payment for fiscal year 2007

Medtronic Suits Up For Patent Litigation, Bolsters Legal Team

Medtronic's recent boost in intellectual property protection resources could increase the likelihood of infringement prosecutions against competitors in the near future

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel